Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Inclusion Criteria: 1. Age ≥ 18 years, gender is not limited; 2. Patients with lymphoma diagnosed by histopathology or cytology; 3. Patients requiring multi-cycle chemotherapy; 4. Planned chemotherapy regimen FN risk ≥ 20 % , or 10% \<FN risk \< 20% with high risk factors ; According to the judgment of the investigator, there is a risk of FN occurrence if G-CSF support is not accepted, PEG-rhG-CSF should be used prophylactically from the first cycle; 5. Physical status (KPS) score ≥ 70 points; 6. Expected Survival period of more than 3 months; 7. Normal bone marrow hematopoietic function (ANC ≥1.5×10\^9/L, PLT≥80×10\^9/L, Hb≥75g/L, WBC≥3.0×10\^9/L); 8. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5 times the upper limit of normal value, or≤5 times the upper limit of normal value when there is liver metastasis; total bilirubin (TBIL)≤2.5 times the upper limit of normal value; serum creatinine (Cr)≤2 times the upper limit of normal value; 9. Female patients of childbearing age must be negative in urine pregnancy test before treatment; 10. The testers (or their legal representatives/guardians) must sign an informed consent form. Exclusion Criteria: 1. Lymphoma central involvement; 2. Hematopoietic stem cell transplantation or organ transplantation; 3. Local or systemic infection without adequate control; 4. Severe internal organ dysfunction and occurred in the last 6 months Myocardial infarction; 5. Those who used other test drugs of the same kind or accepted other clinical trials within 4 weeks before enrollmen； 6. Allergy to PEG-rhG-CSF, rhG-CSF and other preparations or proteins expressed by Escherichia coli; 7. Severe mental illness, affecting informed consent and/or adverse reaction expression or observation; 8. Pregnant or lactating female patients; women who refuse to accept contraceptive measures ; 9. Researchers determine unsuited to participate in this trial.